My lower back is really hurting, All the mucus winds up there. Going to have to sign off now.
TED visa vie DAWN-
They are probably going to be rewarded by sneaking this secondary out-- it was a very small study of I believe ten patients and Two had a complete response. 3 partial. That ='s meh.
The entire team at DAWN is white as heck. There is one Oriental lady who has a meaningless job. I don't trust biotechs that don't have a couple Indian scientists of some Israel Dr's... but that's just me.
I'd take the move and move on.
On june 5th DAWN gave investors a slide show.
•Goal is to establish first-in-
class position through rapid
pediatric registration
•Expand to adult
populations in parallel
•Deep expertise in oncology,
pediatric, and rare disease
development, registration,
and commercialization
•Extensive network in the
global pediatric oncology
community
•Proven track record of
success in building
biopharma companies
•Potential to be first-in-class
oral, CNS-penetrant pan-RAFi
•Potentially the first approval in
a market with no standard of
care
•Monotherapy CRs and PRs in
pediatric low-grade glioma
(pLGG)
•Breakthrough Therapy
Designation, Rare Pediatric
Disease Designation
•Two clinical-stage MEKi
assets, in-licensed for
combination trial
•Projected cash runway into<----------------
2024
Then a few days later secondary.
TED visa vie DAWN-
They are probably going to be rewarded by sneaking this secondary out-- it was a very small study of I believe ten patients and Two had a complete response. 3 partial. That ='s meh.
The entire team at DAWN is white as heck. There is one Oriental lady who has a meaningless job. I don't trust biotechs that don't have a couple Indian scientists of some Israel Dr's... but that's just me.
I'd take the move and move on.
On june 5th DAWN gave investors a slide show.
•Goal is to establish first-in-
class position through rapid
pediatric registration
•Expand to adult
populations in parallel
•Deep expertise in oncology,
pediatric, and rare disease
development, registration,
and commercialization
•Extensive network in the
global pediatric oncology
community
•Proven track record of
success in building
biopharma companies
•Potential to be first-in-class
oral, CNS-penetrant pan-RAFi
•Potentially the first approval in
a market with no standard of
care
•Monotherapy CRs and PRs in
pediatric low-grade glioma
(pLGG)
•Breakthrough Therapy
Designation, Rare Pediatric
Disease Designation
•Two clinical-stage MEKi
assets, in-licensed for
combination trial
•Projected cash runway into<----------------
2024
Then a few days later secondary.
